Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial

@article{Solomkin2017AssessingTE,
  title={Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial},
  author={Joseph S. Solomkin and David Evans and Algirdas {\vS}lepavi{\vc}ius and Patrick Lee and Andrew Marsh and Larry Tsai and Joyce A. Sutcliffe and Patrick T. Horn},
  journal={JAMA Surgery},
  year={2017},
  volume={152},
  pages={224–232}
}
Importance Eravacycline is a novel, fully synthetic fluorocycline antibiotic of the tetracycline class with in vitro activity against clinically important gram-negative, gram-positive aerobic, and facultative bacteria including most of those resistant to cephalosporins, fluoroquinolones, &bgr;-lactam/&bgr;-lactamase inhibitors, multidrug resistant strains and carbapenem-resistant Enterobacteriaceae, and most anaerobic pathogens. Objective To evaluate the efficacy and safety of eravacycline… Expand
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections
  • J. Solomkin, J. Gardovskis, +4 authors L. Tsai
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2018
TLDR
Treatment with eravacycline was noninferior to meropenem in adult patients with cIAI, including infections caused by resistant pathogens, exceeding the prespecified margin. Expand
Efficacy and Tolerability of Eravacycline in Bacteremic Patients with Complicated Intra-Abdominal Infection: A Pooled Analysis from the IGNITE1 and IGNITE4 Studies.
TLDR
Eravacycline demonstrated a similar clinical outcome and microbiologic eradication rate as comparator carbapenems in patients with cIAI and associated secondary bacteremia and safety in the microbiologic-intent-to-treat population (micro-ITT) was assessed. Expand
Eravacycline for the treatment of complicated intra-abdominal infections
TLDR
Eravacycline may be particularly suitable for the treatment of cIAIs, and results from clinical trials and real-world data are expected in specific subgroups of patients to confirm the safety profile and efficacy observed in registration trials. Expand
The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
TLDR
The clinical efficacy of eravacycline is as high as that of the comparator drugs in the treatment of cIAIs and this antibiotic is as well tolerated as the comparators. Expand
A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
TLDR
In this real-world setting, eravacycline demonstrated a similar high level of clinical efficacy as seen in clinical trials, 94%, in a variety of infections, including against multidrug-resistant bacteria, and was well tolerated. Expand
Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.
TLDR
Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms. Expand
Eravacycline: A Review in Complicated Intra-Abdominal Infections
TLDR
In two pivotal double-blind, multinational trials in this patient population, eravacycline was noninferior to intravenous ertapenem or meropenem at the test-of-cure visit in terms of clinical response rates in all prespecified populations. Expand
Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited!
TLDR
These two antibiotic classes have no well-defined or an unpredictable pharmacokinetic and pharmacodynamic profile which hampers their efficacy whilst enhancing the risk for adverse effects and toxicity. Expand
Eravacycline, a newly approved fluorocycline
  • Y. R. Lee, C. Burton
  • Medicine
  • European Journal of Clinical Microbiology & Infectious Diseases
  • 2019
Complicated intra-abdominal infections (cIAIs) are commonly associated with multimicroorganisms and treatment choices are becoming narrower due to developing resistance, especially in theExpand
Eravacycline: The Tetracyclines Strike Back
TLDR
EravacyCline is a new tetracycline antibiotic with a broad spectrum of activity that has demonstrated efficacy in the treatment of cIAIs and although it has activity against multidrug-resistant organisms, data are limited for other indications. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections: Results of a Double-Blind, Randomized Comparative Phase III Trial
TLDR
The results of this trial suggest that ertapenem may be a useful option that could eliminate the need for combination and/or multidosed antibiotic regimens for the empiric treatment of intraabdominal infections. Expand
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
TLDR
Doripenem (500 mg q8h) was effective in the treatment of cIAI, was therapeutically noninferior to meropenem and was well tolerated in the population studied. Expand
Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections
TLDR
Both dose regimens of eravacycline were as efficacious as the comparator, ertapenem, in patients with cIAI and were well tolerated and support the continued development of ervacyclines for the treatment of serious infections, including those caused by drug-resistant Gram-negative pathogens. Expand
Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens
TLDR
Eravacycline has the potential to be a promising new intravenous (i.v.)/oral antibiotic for the empirical treatment of complicated hospital/health care infections and moderate-to-severe community-acquired infections. Expand
Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacterbaumannii Infections
TLDR
Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. Expand
Appropriateness of Empirical Treatment and Outcome in Bacteremia Caused by Extended-Spectrum-β-Lactamase-Producing Bacteria
TLDR
In conclusion, ESBL bacteremia occurs mostly in patients with comorbidities requiring frequent hospitalization, and 84% of episodes were health care associated, and factors other than inappropriate therapy within <24 h determined day 30 mortality. Expand
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
  • J. Mazuski, L. Gasink, +6 authors J. Pachl
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2016
In this randomized phase 3 trial, ceftazidime-avibactam plus metronidazole was noninferior to meropenem in treating complicated intra-abdominal infection, with similar efficacy againstExpand
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
TLDR
This phase 3 trial compared ceftolozane/tazobactam plus metronidazole vs meropenem for the treatment of complicated intra-abdominal infections with high rates of presumed microbiological eradication of Enterobacteriaceae and Pseudomonas aeruginosa. Expand
Current strategies for the treatment of complicated intraabdominal infections
TLDR
The microbiology and recent trends in antibiotic resistance most relevant to cIAIs are highlighted, recommendations for treatment using currently available antimicrobials are provided, and antibiotics in development with potential roles in managing cIAI are introduced. Expand
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
TLDR
Eravacycline is a promising intravenous and oral fluorocycline that may offer an alternative treatment option for patients with serious infections, particularly those caused by multidrug-resistant Gram-negative pathogens. Expand
...
1
2
3
...